Palvella Therapeutics PVLA
Palvella Therapeutics, Inc. · Nasdaq · Pharmaceutical Preparations
$147.47+10.95%close on Oct. 28, 2026 · volume 368K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 21, 2026 | Kathleen Goin Chief Operating Officer | Sold 10b5-1 plan | 4,313 | $124.58 $123.62-$126.19 | $537,307 |
| Oct. 14, 2026 | George M. Jenkins director | Sold 10b5-1 plan | 7,174 | $123.49 $121.14-$126.55 | $885,914 |
| Oct. 13, 2026 | George M. Jenkins director | Sold 10b5-1 plan | 7,174 | $130.36 $128.52-$133.72 | $935,232 |
| Oct. 12, 2026 | George M. Jenkins director | Sold 10b5-1 plan | 13,152 | $133.69 $132.62-$136.44 | $1.76 million |
| Sept. 16, 2026 | Kathleen Goin Chief Operating Officer | Sold 10b5-1 plan | 4,302 | $152.24 $151.16-$153.24 | $654,923 |
| Sept. 15, 2026 | George M. Jenkins director | Sold 10b5-1 plan | 1,777 | $150.14 $149.38-$151.33 | $266,806 |
| Sept. 14, 2026 | George M. Jenkins director | Sold 10b5-1 plan | 13,352 | $151.96 $151.46-$153.10 | $2.03 million |
| Sept. 11, 2026 | George M. Jenkins director | Sold 10b5-1 plan | 12,371 | $151.28 $150.62-$153.06 | $1.87 million |
| Sept. 2, 2026 | Christopher P. Kiritsy director | Sold | 313 | $157.00 | $49,141 |
| Aug. 19, 2026 | Kathleen Goin Chief Operating Officer | Sold 10b5-1 plan | 4,302 | $152.21 $151.39-$156.77 | $654,791 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 15 →Other events · Financial statements and exhibits
AI summary, unreviewedPalvella Therapeutics Announces FDA Acceptance and Priority Review of QTORIN Rapamycin NDA for Microcystic Lymphatic Malformations, PDUFA Date February 28, 2027